FDA panel nixes Capricor's Duchenne drug over efficacy concerns
31 July 2026 · filed under 638630d19c3b
An FDA advisory panel voted against Capricor Therapeutics’ treatment for Duchenne muscular dystrophy, concluding that the clinical data submitted did not provide “substantial evidence” of efficacy, according to STAT News.
The panel’s assessment centers on the strength of the trial evidence Capricor presented to support the drug’s benefit for patients with the condition. STAT News reported the panel’s conclusion as part of its regular roundup of pharmaceutical industry news, published July 30.
The bulletin did not specify the vote count, the panel members’ individual reasoning, or the specific trial data reviewed. Nor did it report Capricor’s response to the outcome or any indication of the company’s next steps.
The advisory panel’s vote is one of several items STAT News covered in the same dispatch, which also noted a Federal Trade Commission lawsuit against Hims & Hers. STAT News framed both items under its regular “Pharmalot” briefing format, a digest of pharmaceutical and biotech developments.
Readers seeking the full trial data, the panel’s voting breakdown, or Capricor’s official statement should consult the original STAT News report, linked in the source material accompanying this dispatch. The Specola’s log records only what the cited dispatch itself states, and no further detail on the panel’s deliberations was available in the material reviewed.